RxDoctor Payments Data

Yvonne Valencia

Family · Kings Mountain, NCNPI 1477102143

Payments from drug & device makers

$3,477in general payments, 2019–2025

Across 216 payments — averaging $16.10 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$868
  • AstraZeneca$586
  • Lilly USA, LLC$366
  • Novo Nordisk$310
  • Bayer$245
  • GSK$168
  • plus $933 from 21 others

What the payments were for

  • Food & beverage$3,463100%
  • Education$140%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$3,477 in reported general payments places this provider in the 90th percentile of 4,522 family providers in North Carolina.

See all family providers in North Carolina

Medicare billing

Part B allowed, 2024
$793
Medicare patients
38
Services billed
112

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide120$152,774
FarxigaDapagliflozin Propanediol66$98,778
EliquisApixaban56$61,665
JardianceEmpagliflozin60$60,115
RybelsusSemaglutide23$31,064
TrulicityDulaglutide25$26,980
MounjaroTirzepatide28$25,943
LinzessLinaclotide13$16,920
XareltoRivaroxaban19$14,414
Trelegy ElliptaFluticasone/Umeclidin/Vilanter18$13,297
SymbicortBudesonide/Formoterol Fumarate57$12,810
Tresiba Flextouch U-100Insulin Degludec13$10,413
Breztri AerosphereBudesonide/Glycopyr/Formoterol16$10,139
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog22$9,929
Fiasp FlextouchInsulin Aspart (Niacinamide)13$9,304

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$310$183,838143 claims
AstraZenecaFarxiga, Symbicort, Breztri Aerosphere$586$121,728139 claims
PfizerEliquis$38$61,66556 claims
Boehringer IngelheimJardiance$148$60,11560 claims
Lilly USA, LLCTrulicity, Mounjaro$366$52,92353 claims
GSKTrelegy Ellipta, Incruse Ellipta$168$20,81639 claims
AbbVieLinzess$868$16,92013 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 4,522 family providers in North Carolina.

Other family in Kings Mountain

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →